Roche breast cancer drug Patoju monoantigen has been approved for sale

Recently, the State Drug Administration approved the import registration application for Pertuzumab Injection, a combination of cocoonumab monoantigen and chemotherapy for complementary treatment of human skin growth factor 2 (HER2) positive early breast cancer patients with a high risk of recurrence.
cancer is the most common malignant tumor in women. After HER2-positive early breast cancer patients received Hersheytine combined chemotherapy, about a third of patients still relapsed or died 10-11 years later, with a higher rate of recurrence or death in high-risk early stage breast cancer patients. A new anti-HER2 drug developed by Roche produces an anti-HER2 effect by inhibiting HER2 heterogeneous and ogeneous dismersions. Global Key Phase III complementary therapy studies show that, compared with the current standard treatment of quercilla bead monoantigen anti-combination chemotherapy, Patoju single-anti-combination virulent and chemotherapy is used for her2-positive early breast cancer patients with high risk of recurrence, significantly improving the survival of patients without invasive disease, adverse reactions can be controlled. In view of the obvious clinical benefits/risk advantages of this product, on December 17, the State Drug Administration approved the import registration of this product, in combination with qutojudan and chemotherapy for the complementary treatment of HER2-positive early breast cancer patients with high risk of recurrence.
In accordance with the spirit of the CPC Central Committee and the State Council on deepening the reform of the drug review and approval system, the State Drug Administration encourages simultaneous domestic and foreign research and development of innovative drugs, declares registration, and directly approves the listing of clinical trial data obtained through international multi-center clinical trials, which meet the requirements related to drug registration, so that patients in China can use innovative drugs with precise efficacy and controllable safety risks as soon as possible, so as to better meet the needs of the general public. (Official website of the State Drug Administration)